ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Our lead product, anti-VISTA, is partnered with Janssen for the treatment of cancer and is currently in a Phase I clinical trial. Our second product, VISTA agonists, is partnered with Hoffmann-La Roche for the treatment of autoimmune diseases. Our third product, anti-CD40L, is partnered with Sanofi for the treatment of autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds.

Our core competencies are discovery, target biology and pre-clinical drug development.


The ImmuNext team combines expert immunology, preclinical development and business development in a tight-knit, well-coordinated team.

Corporate Site

ImmuNext is embedded within the Dartmouth-Hitchcock Medical Center in Lebanon, NH, which affords excellent access to both upstream academic research and downstream translational medicine.


Lebanon, NH provides us with a great combination of intellectual stimulation from Dartmouth College and the beauty of rural New England.